• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immune checkpoint inhibitors and allogeneic transplant in lymphoid malignancies: a deceptive friend story.

作者信息

Farttoosi Mohammed Al, El Cheikh Jean

机构信息

College of Medicine, University of Basrah, Basrah, Iraq.

Bone Marrow Transplantation Program and Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.

出版信息

Bone Marrow Transplant. 2021 Nov;56(11):2624-2625. doi: 10.1038/s41409-021-01396-6. Epub 2021 Jul 24.

DOI:10.1038/s41409-021-01396-6
PMID:34304253
Abstract
摘要

相似文献

1
Immune checkpoint inhibitors and allogeneic transplant in lymphoid malignancies: a deceptive friend story.免疫检查点抑制剂与淋巴细胞恶性肿瘤中的同种异体移植：一个似友非友的故事
Bone Marrow Transplant. 2021 Nov;56(11):2624-2625. doi: 10.1038/s41409-021-01396-6. Epub 2021 Jul 24.
2
Correction to: Immune checkpoint inhibitors and allogeneic transplant in lymphoid malignancies: a deceptive friend story.对《免疫检查点抑制剂与淋巴细胞恶性肿瘤的异基因移植：一个具有欺骗性的朋友的故事》的勘误
Bone Marrow Transplant. 2022 Jun;57(6):1052. doi: 10.1038/s41409-022-01672-z.
3
Correlation of graft immune composition with outcomes after allogeneic stem cell transplantation: Moving towards a perfect transplant.同种异体干细胞移植后移植物免疫组成与结果的相关性：迈向完美移植。
Cell Immunol. 2018 Jan;323:1-8. doi: 10.1016/j.cellimm.2017.11.002. Epub 2017 Nov 7.
4
The Role of Immune Checkpoint Molecules for Relapse After Allogeneic Hematopoietic Cell Transplantation.免疫检查点分子在异基因造血细胞移植后复发中的作用。
Front Immunol. 2021 Mar 5;12:634435. doi: 10.3389/fimmu.2021.634435. eCollection 2021.
5
Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: A single-center analysis.实体器官移植受者转移性癌症患者接受免疫检查点抑制剂治疗的临床结局：单中心分析。
Cancer. 2020 Nov 1;126(21):4780-4787. doi: 10.1002/cncr.33134. Epub 2020 Aug 12.
6
Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma: A Retrospective Cohort Study.经典型霍奇金淋巴瘤免疫检查点抑制后采用移植后环磷酰胺的非清髓性异基因移植：一项回顾性队列研究
Biol Blood Marrow Transplant. 2020 Sep;26(9):1679-1688. doi: 10.1016/j.bbmt.2020.06.012. Epub 2020 Jun 24.
7
[Immune checkpoint inhibitors and allogeneic hematopoietic stem cell transplantation].[免疫检查点抑制剂与异基因造血干细胞移植]
Rinsho Ketsueki. 2017;58(5):506-513. doi: 10.11406/rinketsu.58.506.
8
Rapid and sustained response to immune checkpoint inhibition in cutaneous squamous cell carcinoma after allogenic hematopoietic cell transplant for sézary syndrome.异基因造血细胞移植治疗蕈样肉芽肿后皮肤鳞状细胞癌对免疫检查点抑制的快速和持续反应。
J Immunother Cancer. 2019 Dec 4;7(1):338. doi: 10.1186/s40425-019-0801-z.
9
Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation.移植后环磷酰胺可降低接受同种异体造血干细胞移植后免疫检查点抑制剂治疗的急性髓系白血病/骨髓增生异常综合征患者急性移植物抗宿主病的发生率。
J Immunother Cancer. 2021 Feb;9(2). doi: 10.1136/jitc-2020-001818.
10
Immune checkpoints in hematologic malignancies: What made the immune cells and clinicians exhausted!血液系统恶性肿瘤中的免疫检查点：是什么让免疫细胞和临床医生感到疲惫不堪！
J Cell Physiol. 2020 Dec;235(12):9080-9097. doi: 10.1002/jcp.29769. Epub 2020 May 7.

引用本文的文献

1
The optimal management of relapsed and refractory Hodgkin lymphoma: post-brentuximab and checkpoint inhibitor failure.复发和难治性霍奇金淋巴瘤的最佳治疗策略：博纳吐珠单抗和检查点抑制剂治疗失败后的选择。
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):510-518. doi: 10.1182/hematology.2023000450.
2
The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma.嵌合抗原受体T细胞疗法在复发/难治性霍奇金淋巴瘤中的新兴作用
J Pers Med. 2022 Feb 1;12(2):197. doi: 10.3390/jpm12020197.

本文引用的文献

1
Molecular biology of Hodgkin lymphoma.霍奇金淋巴瘤的分子生物学。
Leukemia. 2021 Apr;35(4):968-981. doi: 10.1038/s41375-021-01204-6. Epub 2021 Mar 8.
2
Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study.抗程序性细胞死亡-1单克隆抗体在异基因造血细胞移植前后用于复发或难治性霍奇金淋巴瘤的安全性和有效性：一项多中心回顾性研究
Int J Hematol. 2020 Nov;112(5):674-689. doi: 10.1007/s12185-020-02960-4. Epub 2020 Aug 3.
3
Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma: A Retrospective Cohort Study.
经典型霍奇金淋巴瘤免疫检查点抑制后采用移植后环磷酰胺的非清髓性异基因移植：一项回顾性队列研究
Biol Blood Marrow Transplant. 2020 Sep;26(9):1679-1688. doi: 10.1016/j.bbmt.2020.06.012. Epub 2020 Jun 24.
4
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.帕博利珠单抗治疗复发或难治性原发性纵隔大 B 细胞淋巴瘤。
J Clin Oncol. 2019 Dec 1;37(34):3291-3299. doi: 10.1200/JCO.19.01389. Epub 2019 Oct 14.
5
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087.帕博利珠单抗治疗复发或难治性霍奇金淋巴瘤：KEYNOTE-087 的 2 年随访结果。
Blood. 2019 Oct 3;134(14):1144-1153. doi: 10.1182/blood.2019000324. Epub 2019 Aug 13.
6
Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide.免疫检查点抑制剂作为异基因移植后环磷酰胺桥接治疗的手段。
Blood Adv. 2018 Sep 11;2(17):2226-2229. doi: 10.1182/bloodadvances.2018019208.
7
Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil.异基因造血干细胞移植治疗霍奇金淋巴瘤中 PD-1 阻断的管理建议：驾驭必要之恶。
Blood. 2018 Jul 5;132(1):9-16. doi: 10.1182/blood-2018-02-811174. Epub 2018 May 2.
8
Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.纳武利尤单抗治疗复发或难治性霍奇金淋巴瘤：真实世界经验。
Ann Oncol. 2017 Oct 1;28(10):2496-2502. doi: 10.1093/annonc/mdx341.
9
PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.异基因造血细胞移植后复发淋巴瘤的程序性死亡受体-1阻断治疗：缓解率高但移植物抗宿主病频繁。
Blood. 2017 Jul 13;130(2):221-228. doi: 10.1182/blood-2017-01-761346. Epub 2017 May 3.
10
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.纳武利尤单抗用于自体干细胞移植和维布妥昔单抗均治疗失败后的经典型霍奇金淋巴瘤：一项多中心、多队列、单臂2期试验。
Lancet Oncol. 2016 Sep;17(9):1283-94. doi: 10.1016/S1470-2045(16)30167-X. Epub 2016 Jul 20.